Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ALXN2350

PreclinicalSmall molecule

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

BAG3 Mutation Associated Dilated CardiomyopathyRecruiting

BAG3 Mutation Associated Dilated CardiomyopathyPreclinical

Recruiting

Timeline

Expected Milestones

Q1 2032

PreclinicalRecruiting

BAG3 Mutation Associated Dilated Cardiomyopathy

NCT07218887

Clinical

Trials by Indication[1]

BAG3 Mutation Associated Dilated Cardiomyopathy1 trial

A Phase 1/2, Open-Label, Multicenter, Dose Finding and Dose Expansion Study to Investigate the Safety, Tolerability, and Efficacy of ALXN2350 Gene Therapy in Adult Participants With BAG3 Mutation Associated Dilated Cardiomyopathy

Recruiting· AstraZeneca logo

AstraZeneca·Preclinical·NCT07218887·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ALXN2350. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ALXN2350 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ALXN2350. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AstraZeneca

Related News